148 related articles for article (PubMed ID: 19267102)
21. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
22. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
23. Significance of Estrogen/Progesterone Receptor Expression in Metaplastic Breast Carcinoma.
Hashmi AA; Mallick BA; Rashid K; Malik UA; Zia S; Zia F; Irfan M
Dis Markers; 2024; 2024():2540356. PubMed ID: 38601434
[TBL] [Abstract][Full Text] [Related]
24. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
25. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
26. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.
Yang XR; Chang-Claude J; Goode EL; Couch FJ; Nevanlinna H; Milne RL; Gaudet M; Schmidt MK; Broeks A; Cox A; Fasching PA; Hein R; Spurdle AB; Blows F; Driver K; Flesch-Janys D; Heinz J; Sinn P; Vrieling A; Heikkinen T; Aittomäki K; Heikkilä P; Blomqvist C; Lissowska J; Peplonska B; Chanock S; Figueroa J; Brinton L; Hall P; Czene K; Humphreys K; Darabi H; Liu J; Van 't Veer LJ; van Leeuwen FE; Andrulis IL; Glendon G; Knight JA; Mulligan AM; O'Malley FP; Weerasooriya N; John EM; Beckmann MW; Hartmann A; Weihbrecht SB; Wachter DL; Jud SM; Loehberg CR; Baglietto L; English DR; Giles GG; McLean CA; Severi G; Lambrechts D; Vandorpe T; Weltens C; Paridaens R; Smeets A; Neven P; Wildiers H; Wang X; Olson JE; Cafourek V; Fredericksen Z; Kosel M; Vachon C; Cramp HE; Connley D; Cross SS; Balasubramanian SP; Reed MW; Dörk T; Bremer M; Meyer A; Karstens JH; Ay A; Park-Simon TW; Hillemanns P; Arias Pérez JI; Menéndez Rodríguez P; Zamora P; Benítez J; Ko YD; Fischer HP; Hamann U; Pesch B; Brüning T; Justenhoven C; Brauch H; Eccles DM; Tapper WJ; Gerty SM; Sawyer EJ; Tomlinson IP; Jones A; Kerin M; Miller N; McInerney N; Anton-Culver H; Ziogas A; Shen CY; Hsiung CN; Wu PE; Yang SL; Yu JC; Chen ST; Hsu GC; Haiman CA; Henderson BE; Le Marchand L; Kolonel LN; Lindblom A; Margolin S; Jakubowska A; Lubiński J; Huzarski T; Byrski T; Górski B; Gronwald J; Hooning MJ; Hollestelle A; van den Ouweland AM; Jager A; Kriege M; Tilanus-Linthorst MM; Collée M; Wang-Gohrke S; Pylkäs K; Jukkola-Vuorinen A; Mononen K; Grip M; Hirvikoski P; Winqvist R; Mannermaa A; Kosma VM; Kauppinen J; Kataja V; Auvinen P; Soini Y; Sironen R; Bojesen SE; Ørsted DD; Kaur-Knudsen D; Flyger H; Nordestgaard BG; Holland H; Chenevix-Trench G; Manoukian S; Barile M; Radice P; Hankinson SE; Hunter DJ; Tamimi R; Sangrajrang S; Brennan P; McKay J; Odefrey F; Gaborieau V; Devilee P; Huijts PE; Tollenaar RA; Seynaeve C; Dite GS; Apicella C; Hopper JL; Hammet F; Tsimiklis H; Smith LD; Southey MC; Humphreys MK; Easton D; Pharoah P; Sherman ME; Garcia-Closas M
J Natl Cancer Inst; 2011 Feb; 103(3):250-63. PubMed ID: 21191117
[TBL] [Abstract][Full Text] [Related]
27. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.
Ambroise M; Ghosh M; Mallikarjuna VS; Kurian A
Asian Pac J Cancer Prev; 2011; 12(3):625-9. PubMed ID: 21627355
[TBL] [Abstract][Full Text] [Related]
29. [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].
Liu RB; Zhou XH; Wang JN; Liang HZ; Li XX; Wu ZH; Ye JL; Wang SM
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3397-400. PubMed ID: 19159568
[TBL] [Abstract][Full Text] [Related]
30. CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary.
Bachmann C; Grischke EM; Fehm T; Staebler A; Schittenhelm J; Wallwiener D
J Cancer Res Clin Oncol; 2013 Apr; 139(4):551-6. PubMed ID: 23224376
[TBL] [Abstract][Full Text] [Related]
31. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
32. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients.
Bae SY; Lee SK; Koo MY; Hur SM; Choi MY; Cho DH; Kim S; Choe JH; Lee JE; Kim JH; Kim JS; Nam SJ; Yang JH
Breast Cancer Res Treat; 2011 Apr; 126(2):471-8. PubMed ID: 21287362
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
Almasri NM; Al Hamad M
Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
35. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
[TBL] [Abstract][Full Text] [Related]
36. Medullary breast carcinoma: a pathogenic review and immunohistochemical study using tissue microarray.
Lee M; Jara-Lazaro AR; Cheok PY; Thike AA
Singapore Med J; 2022 Jul; 63(7):394-401. PubMed ID: 33866710
[TBL] [Abstract][Full Text] [Related]
37. Expression of androgen receptor in primary breast carcinoma and its relation with clinicopathologic features, estrogen, progesterone, and her-2 receptor status.
Vellaisamy G; Tirumalae R; Inchara YK
J Cancer Res Ther; 2019; 15(5):989-993. PubMed ID: 31603099
[TBL] [Abstract][Full Text] [Related]
38. [Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?].
Mainka P; Kahlert S; Kirchner T; Mayr D; Diebold J
Pathologe; 2008 Nov; 29 Suppl 2():363-9. PubMed ID: 18807040
[TBL] [Abstract][Full Text] [Related]
39. Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer.
Umekita Y; Ohi Y; Souda M; Rai Y; Sagara Y; Sagara Y; Tamada S; Tanimoto A
Diagn Pathol; 2011 Apr; 6():36. PubMed ID: 21496280
[TBL] [Abstract][Full Text] [Related]
40. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
